Masking the immunotoxicity of interleukin-12 by fusing it with a domain of its receptor via a tumour-protease-cleavable linker
Menée à l'aide de lignées cellulaires et de modèles murins d'adénocarcinome sous-cutané ou de mélanome orthotopique, cette étude met en évidence l'intérêt, pour réduire l'immunotoxicité de l'interleukine IL-12, de masquer cette dernière en la fusionnant à un domaine de son récepteur au moyen d'une liaison clivable par une protéase tumorale
Immune-checkpoint inhibitors have shown modest efficacy against immunologically ‘cold’ tumours. Interleukin-12 (IL-12)—a cytokine that promotes the recruitment of immune cells into tumours as well as immune cell activation, also in cold tumours—can cause severe immune-related adverse events in patients. Here, by exploiting the preferential overexpression of proteases in tumours, we show that fusing a domain of the IL-12 receptor to IL-12 via a linker cleavable by tumour-associated proteases largely restricts the pro-inflammatory effects of IL-12 to tumour sites. In mouse models of subcutaneous adenocarcinoma and orthotopic melanoma, masked IL-12 delivered intravenously did not cause systemic IL-12 signalling and eliminated systemic immune-related adverse events, led to potent therapeutic effects via the remodelling of the immune-suppressive microenvironment, and rendered cold tumours responsive to immune-checkpoint inhibition. We also show that masked IL-12 is activated in tumour lysates from patients. Protease-sensitive masking of potent yet toxic cytokines may facilitate their clinical translation.